<p>作者：Jaimy Lee</p>
<p>该注射剂与 Zepbound 和 Foundayo 不同。它包含 GIP、GLP-1 和胰高血糖素。</p>
<p>在 5 月 11 日，礼来的团队在纽约敲响开盘钟后，纽约证券交易所的景象。（照片由 ANGELA WEISS / AFP 通过 Getty Images 提供）</p>
<p>礼来的下一代每周减重注射剂可能比长期以来被视为减重金标准的减肥手术更有效。</p>
<p>在一项名为 TRIUMPH-1 的三期试验中，参与者服用了 4 毫克、9 毫克或 12 毫克的礼来 retatrutide，持续约一年半。服用最高剂量的人体重减轻了 28.3%，而近一半的参与者体重减轻超过 30%。服用最低剂量的人仍然减轻了 19.0% 的体重。</p>
<p>该研究的结果是 retatrutide 可能是开发中最有效的减肥药物的最新信号。</p>
<p>因此，retatrutide 是礼来（LLY）肥胖药物组合中备受期待的新增成员，该组合已经包括每周一次的 GLP-1/GIP 注射剂 Zepbound 和每日一次的非肽 GLP-1 药丸 Foundayo。它有时被称为 “三重 G”，因为它包含 GIP、GLP-1 和胰高血糖素。</p>
<p>“Retatrutide 可以进一步巩固礼来在满足患者需求和偏好方面的承诺，” 礼来心脏代谢健康部总裁 Kenneth Custer 在一份声明中表示。</p>
<p>这款仍在实验阶段的注射剂被广泛视为最适合重度肥胖患者的疗法，礼来指出，减重幅度与接受减肥手术的患者相当。</p>
<p>在试验中，服用 retatrutide 的人经历了与其他 GLP-1 药物常见的类似副作用。根据剂量的不同，28.6% 到 42.4% 的参与者报告了恶心，25.3% 到 32.0% 的人报告了腹泻。约 11% 的高剂量 retatrutide 患者因副作用停止参与试验。</p>
<p>在所谓的肽类用户中，通常是参与健身或外貌提升社区的人，retatrutide 的非处方使用变得流行。人们购买原料，然后自行混合和注射。</p>
<p>-Jaimy Lee</p>
<p>此内容由 MarketWatch 创作，MarketWatch 由道琼斯公司运营。MarketWatch 与道琼斯新闻通讯和《华尔街日报》独立出版。</p>
<p>（完）道琼斯新闻通讯</p>
<p>05-21-26 0811ET</p>

礼来

2 倍做多 LLY ETF - Defiance

2 倍做多 LLY ETF - Direxion

<p>礼来的实验性减肥注射剂 retatrutide 在第三阶段试验中显示出显著的疗效，参与者的体重最多减少了 28.3%。近一半的参与者体重减轻超过 30%。这种结合了 GIP、GLP-1 和胰高血糖素的药物可能在疗效上与减肥手术相媲美。副作用包括恶心和腹泻，一些参与者因这些问题而中止治疗。预计 retatrutide 将增强礼来的肥胖治疗产品组合</p>

<p>By Jaimy Lee</p>
<div class="lb-trans"><p>作者：Jaimy Lee</p>
</div><p>The injection is different than Zepbound and Foundayo. It includes GIP, GLP-1, and glucagon</p>
<div class="lb-trans"><p>该注射剂与 Zepbound 和 Foundayo 不同。它包含 GIP、GLP-1 和胰高血糖素。</p>
</div><p>A view of the New York Stock Exchange after Eli Lilly's team rang the opening bell in New York on May 11. (Photo by ANGELA WEISS / AFP via Getty Images)</p>
<div class="lb-trans"><p>在 5 月 11 日，礼来的团队在纽约敲响开盘钟后，纽约证券交易所的景象。（照片由 ANGELA WEISS / AFP 通过 Getty Images 提供）</p>
</div><p>Eli Lilly's next-generation weekly weight-loss shot may be more effective than bariatric surgery, which has long been the gold standard for weight loss.</p>
<div class="lb-trans"><p>礼来的下一代每周减重注射剂可能比长期以来被视为减重金标准的减肥手术更有效。</p>
</div><p>In a Phase 3 trial, which is called TRIUMPH-1, participants took 4 mg, 9 mg or 12 mg of Lilly's retatrutide for about a year and a half. People taking the highest dose lost 28.3% of their body weight, while nearly half of the participants lost more than 30% of their body weight. Those taking the lowest dose still lost 19.0% of their body weight.</p>
<div class="lb-trans"><p>在一项名为 TRIUMPH-1 的三期试验中，参与者服用了 4 毫克、9 毫克或 12 毫克的礼来 retatrutide，持续约一年半。服用最高剂量的人体重减轻了 28.3%，而近一半的参与者体重减轻超过 30%。服用最低剂量的人仍然减轻了 19.0% 的体重。</p>
</div><p>The study's results are the latest signal that retatrutide may be the most effective weight-loss medication in development.</p>
<div class="lb-trans"><p>该研究的结果是 retatrutide 可能是开发中最有效的减肥药物的最新信号。</p>
</div><p>As such, retatrutide is a highly anticipated addition to Lilly's (LLY) obesity portfolio, which already includes Zepbound, a weekly GLP-1/GIP shot, and Foundayo, a daily non-peptide GLP-1 pill. It is sometimes referred to as &#34;triple G&#34; because it includes GIP, GLP-1, and glucagon.</p>
<div class="lb-trans"><p>因此，retatrutide 是礼来（LLY）肥胖药物组合中备受期待的新增成员，该组合已经包括每周一次的 GLP-1/GIP 注射剂 Zepbound 和每日一次的非肽 GLP-1 药丸 Foundayo。它有时被称为 “三重 G”，因为它包含 GIP、GLP-1 和胰高血糖素。</p>
</div><p>&#34;Retatrutide could build on Lilly's commitment to match treatments to the needs and preferences of patients,&#34; said Kenneth Custer, president of Lilly Cardiometabolic Health, in a statement.</p>
<div class="lb-trans"><p>“Retatrutide 可以进一步巩固礼来在满足患者需求和偏好方面的承诺，” 礼来心脏代谢健康部总裁 Kenneth Custer 在一份声明中表示。</p>
</div><p>The still-experimental injection has largely been viewed as a therapy that would work best in people with severe obesity, and Lilly noted that the amount of weight loss is on par with what patients see after getting bariatric surgery.</p>
<div class="lb-trans"><p>这款仍在实验阶段的注射剂被广泛视为最适合重度肥胖患者的疗法，礼来指出，减重幅度与接受减肥手术的患者相当。</p>
</div><p>People taking retatrutide in the trial experienced similar side effects that are common with other GLP-1 medications. Between 28.6% and 42.4% of participants reported nausea, depending on their dose, and between 25.3% and 32.0% reported diarrhea. About 11% of patients taking the high dose of retatrutide stopped participating in the trial as a result of the side effects.</p>
<div class="lb-trans"><p>在试验中，服用 retatrutide 的人经历了与其他 GLP-1 药物常见的类似副作用。根据剂量的不同，28.6% 到 42.4% 的参与者报告了恶心，25.3% 到 32.0% 的人报告了腹泻。约 11% 的高剂量 retatrutide 患者因副作用停止参与试验。</p>
</div><p>Among so-called peptide users, often people involved in the fitness or looksmaxxing communities, off-label use of retatrutide has become popular. People purchase the raw ingredients and then mix and inject them themselves.</p>
<div class="lb-trans"><p>在所谓的肽类用户中，通常是参与健身或外貌提升社区的人，retatrutide 的非处方使用变得流行。人们购买原料，然后自行混合和注射。</p>
</div><p>-Jaimy Lee</p>
<div class="lb-trans"><p>-Jaimy Lee</p>
</div><p>This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.</p>
<div class="lb-trans"><p>此内容由 MarketWatch 创作，MarketWatch 由道琼斯公司运营。MarketWatch 与道琼斯新闻通讯和《华尔街日报》独立出版。</p>
</div><p>(END) Dow Jones Newswires</p>
<div class="lb-trans"><p>（完）道琼斯新闻通讯</p>
</div><p>05-21-26 0811ET</p>
<div class="lb-trans"><p>05-21-26 0811ET</p>
</div>

礼来的新实验性注射剂实现了 28% 的体重减轻